| Helen Rego Moreira, MD | |
|
300 Congress St, Suite 200, Quincy, MA 02169-0907 | |
| (617) 471-5665 | |
| Not Available |
| Full Name | Helen Rego Moreira |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 15 Years |
| Location | 300 Congress St, Quincy, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396974812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 254783 (Massachusetts) | Secondary |
| 207W00000X | Ophthalmology | MD14392 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nielsen Eye Center, Inc. | 6608828884 | 12 |
News Archive
"More than 4,000 delegates - including government officials, health experts, community leaders, scientists, indigenous populations, youth and people living with HIV - convened from 28-31 August in Sao Paulo, Brazil, for the 6th Latin American and Caribbean Forum on HIV/AIDS and Sexually Transmitted Infections (STIs)," UNAIDS reports in a feature story.
The Ministry of Health of Cote d'Ivoire has declared a yellow fever outbreak in the capital, Abidjan. The outbreak was laboratory confirmed at the beginning of May 2008.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.
› Verified 2 days ago
| Entity Name | Nielsen Eye Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982829669 PECOS PAC ID: 6608828884 Enrollment ID: O20050216000187 |
News Archive
"More than 4,000 delegates - including government officials, health experts, community leaders, scientists, indigenous populations, youth and people living with HIV - convened from 28-31 August in Sao Paulo, Brazil, for the 6th Latin American and Caribbean Forum on HIV/AIDS and Sexually Transmitted Infections (STIs)," UNAIDS reports in a feature story.
The Ministry of Health of Cote d'Ivoire has declared a yellow fever outbreak in the capital, Abidjan. The outbreak was laboratory confirmed at the beginning of May 2008.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.
› Verified 2 days ago
| Entity Name | Medical Eye Care Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386615193 PECOS PAC ID: 9234105503 Enrollment ID: O20050407000344 |
News Archive
"More than 4,000 delegates - including government officials, health experts, community leaders, scientists, indigenous populations, youth and people living with HIV - convened from 28-31 August in Sao Paulo, Brazil, for the 6th Latin American and Caribbean Forum on HIV/AIDS and Sexually Transmitted Infections (STIs)," UNAIDS reports in a feature story.
The Ministry of Health of Cote d'Ivoire has declared a yellow fever outbreak in the capital, Abidjan. The outbreak was laboratory confirmed at the beginning of May 2008.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Helen Rego Moreira, MD 6 Union Park, #5, Boston, MA 02118-3705 Ph: (413) 519-2277 | Helen Rego Moreira, MD 300 Congress St, Suite 200, Quincy, MA 02169-0907 Ph: (617) 471-5665 |
News Archive
"More than 4,000 delegates - including government officials, health experts, community leaders, scientists, indigenous populations, youth and people living with HIV - convened from 28-31 August in Sao Paulo, Brazil, for the 6th Latin American and Caribbean Forum on HIV/AIDS and Sexually Transmitted Infections (STIs)," UNAIDS reports in a feature story.
The Ministry of Health of Cote d'Ivoire has declared a yellow fever outbreak in the capital, Abidjan. The outbreak was laboratory confirmed at the beginning of May 2008.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.
› Verified 2 days ago
David G Lotufo, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1900 Crown Colony Dr, Suite 301, Quincy, MA 02169 Phone: 617-472-5242 Fax: 617-471-5093 | |
Cindy W. Chao, M.D., PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1900 Crown Colony Dr Ste 301, Quincy, MA 02169 Phone: 617-770-4400 Fax: 617-471-5093 | |
Dr. Helene Y Lam, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1250 Hancock St, Ophthalmology Dept, Quincy, MA 02169 Phone: 617-774-0780 Fax: 617-774-0795 | |
Mr. Steven A Nielsen, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 300 Congress St, Suite 201, Quincy, MA 02169 Phone: 617-471-5665 Fax: 617-471-7041 | |
Gary E Borodic, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1261 Furnace Brook Pkwy, Suite 15, Quincy, MA 02169 Phone: 617-770-0011 Fax: 617-770-0030 | |
Dr. Domenic M Strazzulla, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 500 Congress St, Suite 1a-1, Quincy, MA 02169 Phone: 617-770-1505 Fax: 617-479-6832 |